This Week’s Biotech Highlights

Lots of biotech and pharma deal activity is ongoing in Canada and around the world, including Roche’s debt offering to fund its Genentech bid and an unsolicited offer by JLL Partners for Patheon, which was founded in Canada.

New regulations are on the way for organic food in Canada, where cloned animals will be excluded; and for genetic information in the U.S., where the EEOC started hearings to implement Title II of the Genetic Information Nondiscrimination Act.

Regulatory optimism from GTC Biotherapeutics, which started a collaboration with New Zealand’s AgResearch for animal-produced biosimilars; but pessimism from Basilea, which filed for arbitration against J&J after facing delays with their flagship antibiotic; and

More research spending in the U.S. may benefit Canadians, who compete for NIH funds in surprising numbers.

Read more about these developments, as well as the Monday Deal Review, the Wednesday Brain Dump and the Friday Science Review at the Cross-Border Biotech Blog.